Martin David Harp

The company plans to submit its NDA package in the second half of 2026.

Alcon increases its acquisition offer for STAAR Surgical, emphasizing a final deal amid shareholder debates and delays in the merger process.

Xelafaslatide is a small-molecule Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs across multiple retinal diseases and conditions.

The study evaluated thermal dynamics associated with CW-TSCPC and TLT using MicroPulse technology, such as temperature peak, exposure duration, and thermal spread in a simulated ciliary body using computer modeling.

EndoArt is an artificial cornea endothelial layer made of a sterile biocompatible material, acrylic hydrophilic. According to the company it is the first synthetic implant to treat corneal edema.

The trial is evaluating the company’s femtosecond laser trabeculotomy procedure in comparison to selective laser trabeculoplasty

Formosa Pharmaceuticals partners with Rxilient Medical to commercialize APP13007, a new ophthalmic treatment for post-surgery inflammation and pain relief.

Earlier in 2025 it was announced that PainReform had acquired a majority equity interest in LayerBio, focusing on the company’s OcuRing-K technology.

Under the terms of the agreement Iolyx Therapeutics has granted Théa exclusive worldwide development and commercialization rights, excluding Asia, to ILYX-002 for the treatment of ocular surface diseases.

The SAPPHIRE trial evaluating the VisiPlate is currently underway across several sites across the US, with more site activations scheduled for 2026

K8 is a member of a new class of inflammasome-inhibiting drugs called kamuvudines.

Cyclosporine ophthalmic emulsion 0.05% is a topical immunomodulator to increase tear production in patients whose tear production is thought to be reduced due to ocular inflammation associated with dry eye syndrome.

The company noted that this approval marks Celltrion's first Health Canada–approved biologic product in ophthalmology.

This is the first submission for approval under the exclusive license and commercialization agreement for South Korea that was signed between LENZ and Lotus.

HUC1-394 is a peptide-based eye drop for dry eyes being developed by the company.

The DRAGON trial was a 24-month pivotal phase 3 trial evaluating Tinlarebant in adolescent STGD1 patients.

Kiora Pharmaceuticals advances ocular therapies with new patents for KIO-104, targeting retinal inflammation and enhancing treatment options.

To help with education and awareness, Prevent Blindness is providing free, expert-approved educational resources on GA.

Both therapeutics will leverage AGC Biologics’ BravoAAV suspension platform and use an innovative dual AAV vector approach, which splits the therapeutic gene into 2 halves.

HELIOS-3 is a phase 3 registrational program for AXPAXLI (or OTX-TKI) for the treatment of non-proliferative diabetic retinopathy (NPDR).

AAO 2025 revealed that true-color widefield imaging, AI-powered home OCT, and refined FAERS analyses are collectively transforming retinal diagnostics into a more precise, continuous, and safety-aware system.

The topical ophthalmic solution is preservative-free and includes dual lubricants—hyaluronic acid and hydroxypropyl methylcellulose—for patient comfort.

According to the company, this is the first and only single-use kit on the market that includes the diagnostic lens.

Additionally, the FDA approved a monthly dosing option for some patients who may benefit from resuming this dosing schedule across approved indications.

The procedure was conducted as part of the company’s ongoing phase 1 clinical trial.